Compare SVC & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVC | XFOR |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.4M | 332.3M |
| IPO Year | N/A | N/A |
| Metric | SVC | XFOR |
|---|---|---|
| Price | $1.82 | $3.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $2.75 | ★ $28.50 |
| AVG Volume (30 Days) | ★ 1.3M | 571.7K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,873,944,000.00 | $33,979,000.00 |
| Revenue This Year | N/A | $1,276.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2925.74 |
| 52 Week Low | $1.55 | $1.35 |
| 52 Week High | $3.08 | $26.83 |
| Indicator | SVC | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 58.86 |
| Support Level | $1.68 | $3.05 |
| Resistance Level | $1.88 | $3.90 |
| Average True Range (ATR) | 0.08 | 0.27 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 80.30 | 87.25 |
Service Properties Trust is a real estate investment trust that owns hotel properties. These properties are located in the United States, along with Canada and Puerto Rico. The company operates through its hotel investment unit and net lease investments. The firm derives the majority of its revenue from the hotel real estate investments unit. The hotels are distinguished between their service levels, which include full service, select service, and extended stay; and chain scale, which includes luxury, upper upscale, upscale, upper midscale, and midscale. The hotels are extended stay or upscale. Some of the hotel brands include Courtyard by Marriott, Royal Sonesta, Crowne Plaza Hotels & Resorts, and Hyatt Place.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.